» Articles » PMID: 36998464

Amino Acid Metabolic Reprogramming in Tumor Metastatic Colonization

Overview
Journal Front Oncol
Specialty Oncology
Date 2023 Mar 31
PMID 36998464
Authors
Affiliations
Soon will be listed here.
Abstract

Metastasis is considered as the major cause of cancer death. Cancer cells can be released from primary tumors into the circulation and then colonize in distant organs. How cancer cells acquire the ability to colonize in distant organs has always been the focus of tumor biology. To enable survival and growth in the new environment, metastases commonly reprogram their metabolic states and therefore display different metabolic properties and preferences compared with the primary lesions. For different microenvironments in various colonization sites, cancer cells must transfer to specific metabolic states to colonize in different distant organs, which provides the possibility of evaluating metastasis tendency by tumor metabolic states. Amino acids provide crucial precursors for many biosynthesis and play an essential role in cancer metastasis. Evidence has proved the hyperactivation of several amino acid biosynthetic pathways in metastatic cancer cells, including glutamine, serine, glycine, branched chain amino acids (BCAAs), proline, and asparagine metabolism. The reprogramming of amino acid metabolism can orchestrate energy supply, redox homeostasis, and other metabolism-associated pathways during cancer metastasis. Here, we review the role and function of amino acid metabolic reprogramming in cancer cells colonizing in common metastatic organs, including lung, liver, brain, peritoneum, and bone. In addition, we summarize the current biomarker identification and drug development of cancer metastasis under the amino acid metabolism reprogramming, and discuss the possibility and prospect of targeting organ-specific metastasis for cancer treatment.

Citing Articles

A Review on the Role of Human Solute Carriers Transporters in Cancer.

Hossen M, Islam M, Yasin M, Ibrahim M, Das A Health Sci Rep. 2025; 8(1):e70343.

PMID: 39807482 PMC: 11725534. DOI: 10.1002/hsr2.70343.


SLC7A5 regulates tryptophan uptake and PD‑L1 expression levels via the kynurenine pathway in ovarian cancer.

Jiang R, Jin B, Sun Y, Chen Z, Wan D, Feng J Oncol Lett. 2024; 29(1):26.

PMID: 39512508 PMC: 11542159. DOI: 10.3892/ol.2024.14772.


Insights into Metabolic Reprogramming in Tumor Evolution and Therapy.

Chiu C, Guerrero J, Regalado R, Zamora M, Zhou J, Notarte K Cancers (Basel). 2024; 16(20).

PMID: 39456607 PMC: 11506062. DOI: 10.3390/cancers16203513.


PYCR1 regulates TRAIL‑resistance in non‑small cell lung cancer cells by regulating the redistribution of death receptors.

You C, He J, Cao C, Sheng D, Wang L, Huang Z Oncol Lett. 2024; 27(5):216.

PMID: 38549801 PMC: 10973927. DOI: 10.3892/ol.2024.14349.


Bridging the Gap in Understanding Bone Metastasis: A Multifaceted Perspective.

Elaasser B, Arakil N, Mohammad K Int J Mol Sci. 2024; 25(5).

PMID: 38474093 PMC: 10932255. DOI: 10.3390/ijms25052846.


References
1.
Lin A, Abbas S, Kim S, Ortega M, Bouamar H, Escobedo Y . D2HGDH regulates alpha-ketoglutarate levels and dioxygenase function by modulating IDH2. Nat Commun. 2015; 6:7768. PMC: 4515030. DOI: 10.1038/ncomms8768. View

2.
Rainesalo S, Keranen T, Palmio J, Peltola J, Oja S, Saransaari P . Plasma and cerebrospinal fluid amino acids in epileptic patients. Neurochem Res. 2004; 29(1):319-24. DOI: 10.1023/b:nere.0000010461.34920.0c. View

3.
Li B, Cao Y, Meng G, Qian L, Xu T, Yan C . Targeting glutaminase 1 attenuates stemness properties in hepatocellular carcinoma by increasing reactive oxygen species and suppressing Wnt/beta-catenin pathway. EBioMedicine. 2018; 39:239-254. PMC: 6355660. DOI: 10.1016/j.ebiom.2018.11.063. View

4.
Chen W . Clinical applications of PET in brain tumors. J Nucl Med. 2007; 48(9):1468-81. DOI: 10.2967/jnumed.106.037689. View

5.
Zhang K, Zhu W, Wang S, Gao C, Pan J, Du Z . Organ-specific cholesterol metabolic aberration fuels liver metastasis of colorectal cancer. Theranostics. 2021; 11(13):6560-6572. PMC: 8120208. DOI: 10.7150/thno.55609. View